Skip to content

Gross margin at other companies

Castle Biosciences logo
Castle BiosciencesCSTL
77.9%-4.1pp
Guardant Health logo
Guardant HealthGH
64.9%+3.6pp
Insight Molecular Diagnostics Inc. Common Stock logo
Insight Molecular Diagnostics Inc. Common StockIMDX
51.3%-3.0pp
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT
38.7%-0.1pp
Personalis, Inc. logo
Personalis, Inc.PSNL
13.7%-19.6pp
GeneDx Holdings logo
GeneDx HoldingsWGS
69.6%+4.3pp

Other financials

Income statement

See full
Revenue$1.3M+51.7%
Gross profit-$369.0K+49.0%
Operating income-$12.1M+3.0%
Net income-$13.9M+48.3%
EPS (diluted)-$0.10+60.0%

Balance sheet

See full
Cash & equivalents$27.9M+10.6%
Total debt$1.6M-35.1%
Total equity$4.0M+174%
Total assets$34.1M+3.9%

Cash flow

See full
Operating cash flow-$12.1M+2.9%
CapEx$215.0K+131%
Free cash flow-$12.3M+1.9%

Valuation

See full
Market cap$204.13M+58.5%
Enterprise value$177.85M+78.0%
P/S39.8×+10.2×

Profitability

See full
Operating margin-959.6%-133pp
Net margin-876.7%-254pp
FCF margin-1,099.6%

Returns & leverage

See full
Return on equity-710.6%
Debt / equity0.4×
Current ratio1.1×+0.3×

Where this comes from

Calculated from Lucid Diagnostics’s reported figures.

Based on trailing twelve months.

The official record: Lucid Diagnostics’s 10-Q, filed May 13, 2025, on SEC EDGAR. View the filing →

Ask your AI about Lucid Diagnostics's gross margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lucid Diagnostics's gross margin?
Lucid Diagnostics (LUCD) reported gross margin of -66.8% in Q1 2025.
What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.